Report cover image

Global Biomarker Discovery Outsourcing Services Market Size Study, By Biomarker Type (Predictive, Prognostic, Safety, Surrogate Endpoints), By Therapeutic Area (Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas), By Discovery P

Publisher Factview Research
Published Oct 03, 2025
Length 285 Pages
SKU # FAVR20464086

Description

The global biomarker discovery outsourcing services market is valued at approximately USD 14.53 billion in 2024 and is projected to grow with a healthy CAGR of 20.4% over the forecast period 2025-2034. Biomarkers play an essential role in disease diagnosis, prognosis, and therapeutic monitoring, fueling their increasing demand across pharmaceutical and biotechnology industries. The market is experiencing significant growth due to technological advancements in omics technologies (genomics, proteomics, metabolomics), artificial intelligence (AI), and machine learning (ML)-driven biomarker identification. Moreover, the growing adoption of personalized medicine, the rising prevalence of chronic diseases, and the need for high-throughput biomarker discovery solutions are further fueling the outsourcing demand.

The pharmaceutical and biotech industries are increasingly outsourcing biomarker research to contract research organizations (CROs) due to cost efficiency, faster drug development timelines, and access to specialized expertise. AI-powered predictive biomarker discovery, multi-omics integration, and growing strategic collaborations between pharma companies and CROs are reshaping the industry landscape. Furthermore, government initiatives and regulatory agency support for biomarker-based clinical trials, particularly from the U.S. FDA, EMA, and ICH, are driving investment in biomarker validation and accelerating market expansion.

The expansion of R&D investments in biopharmaceuticals is another significant factor propelling market growth. With increasing drug development complexities and the shift toward biologics and cell & gene therapies, pharmaceutical companies are allocating larger budgets to biomarker-driven research. This trend has resulted in a surge in industry-academia partnerships, venture capital funding, and government-backed research programs to facilitate biomarker discovery. In addition, the development of non-invasive liquid biopsy biomarkers and digital pathology solutions is enhancing the efficiency of biomarker-based diagnostics. The integration of AI-driven predictive analytics, real-world data, and automation in biomarker discovery further enhances the role of outsourcing in optimizing biopharmaceutical R&D pipelines and improving drug success rates.

As cost efficiency and regulatory compliance become key priorities, outsourcing to specialized CROs and contract development and manufacturing organizations (CDMOs) has emerged as a strategic approach in the biomarker discovery space. These service providers offer end-to-end biomarker discovery solutions, including early-stage biomarker validation, preclinical and clinical validation, and regulatory compliance support, thereby accelerating time-to-market. The market is also witnessing increasing acquisitions, partnerships, and geographic expansions by CROs to meet the rising demand for biomarker discovery services. Additionally, automation in biomarker analysis, cloud-based bioinformatics, and decentralized clinical trials are playing a vital role in shaping future market dynamics.

Major Market Players Included in this Report are:
  • LabCorp
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific
  • Celerion
  • ICON plc
  • Parexel International (MA) Corporation
  • Proteome Sciences
  • GHO Capital
  • Thermo Fisher Scientific Inc.
  • Evotec
  • Medpace
  • BioAgilytix Labs
  • Covance Inc.
  • WuXi AppTec
  • PPD Inc.
The Detailed Segments and Sub-Segment of the Market are Explained Below:

By Biomarker Type:
  • Predictive Biomarkers
  • Prognostic Biomarkers
  • Safety Biomarkers
  • Surrogate Endpoints
By Therapeutic Area:
  • Oncology
  • Neurology
  • Cardiology
  • Autoimmune Diseases
  • Other Therapeutic Areas
By Discovery Phase:
  • Biomarker Identification
  • Biomarker Validation
  • Biomarker Profiling
  • Biomarker Panel Development
  • Biomarker Selection
By End Use:
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Other End Uses
By Region:

North America:
  • U.S.
  • Canada
  • Mexico
Europe:
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
Asia Pacific:
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
Latin America:
  • Brazil
  • Argentina
Middle East & Africa:
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Years Considered for the Study are as follows:
  • Historical Year – 2022
  • Base Year – 2024
  • Forecast Period – 2024 to 2034
Key Takeaways:
  • Market Estimates & Forecast for 10 years from 2022 to 2034.
  • Annualized revenue & regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with country-level insights.
  • Competitive landscape with information on major industry players.
  • Analysis of key business strategies and recommendations on future market approaches.
  • Supply and demand analysis of the market

Table of Contents

285 Pages
Chapter 1. Global Biomarker Discovery Outsourcing Services Market Executive Summary
1.1. Global Biomarker Discovery Outsourcing Services Market Size & Forecast (2024-2034)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Biomarker Type
1.3.2. By Therapeutic Area
1.3.3. By Discovery Phase
1.3.4. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6 Industry Metrics
1.7 Investment Analysis
1.8 Investment Rationale
1.9. Analyst Recommendation & Conclusion
Chapter 2. Global Biomarker Discovery Outsourcing Services Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Biomarker Discovery Outsourcing Services Market Dynamics
3.1. Market Drivers
3.1.1. Growing Demand for Personalized Medicine & Biomarker-Based Drug Discovery
3.1.2. Increasing Adoption of AI & ML in Biomarker Identification
3.1.3. Expansion of Contract Research Organizations (CROs) in Biomarker Discovery Services
3.2. Market Challenges
3.2.1. Stringent Regulatory Frameworks for Biomarker Validation
3.2.2. High Cost of Biomarker Discovery and Data Analysis
3.3. Market Opportunities
3.3.1. Expansion of Multi-Omics and Big Data Analytics in Biomarker Research
3.3.2. Rising Collaborations Between Pharma Companies and CROs
Chapter 4. Global Biomarker Discovery Outsourcing Services Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Biomarker Type (2024-2034)
5.1. Segment Dashboard
5.2. Revenue Trend Analysis (USD Million/Billion)
5.3. Predictive Biomarkers
5.4. Prognostic Biomarkers
5.5. Safety Biomarkers
5.6. Surrogate Endpoints
Chapter 6. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Therapeutic Area (2024-2034)
6.1. Segment Dashboard
6.2. Revenue Trend Analysis (USD Million/Billion)
6.3. Oncology
6.4. Neurology
6.5. Cardiology
6.6. Autoimmune Diseases
6.7. Other Therapeutic Areas
Chapter 7. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Discovery Phase (2024-2034)
7.1. Segment Dashboard
7.2. Revenue Trend Analysis (USD Million/Billion)
7.3. Biomarker Identification
7.4. Biomarker Validation
7.5. Biomarker Profiling
7.6. Biomarker Panel Development
7.7. Biomarker Selection
Chapter 8. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by End Use (2024-2034)
8.1. Segment Dashboard
8.2. Revenue Trend Analysis (USD Million/Billion)
8.3. Pharmaceutical Companies
8.4. Biotechnology Companies
8.5. Other End Use
Chapter 9. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Region (2024-2034)
9.1. North America
9.1.1. U.S.
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Sweden
9.2.7. Denmark
9.2.8. Norway
9.3. Asia Pacific
9.3.1. Japan
9.3.2. China
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Thailand
9.4. Latin America
9.4.1. Brazil
9.4.2. Argentina
9.5. Middle East & Africa
9.5.1. South Africa
9.5.2. Saudi Arabia
9.5.3. UAE
9.5.4. Kuwait
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. LabCorp
10.1.2. Charles River Laboratories
10.1.3. Thermo Fisher Scientific
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. LabCorp
10.3.2. Charles River Laboratories
10.3.3. Eurofins Scientific
10.3.4. Celerion
10.3.5. ICON plc
10.3.6. Parexel International (MA) Corporation
10.3.7. Proteome Sciences
10.3.8. GHO Capital
10.3.9. Thermo Fisher Scientific Inc.
10.3.10. Evotec
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us